+1 123-456-7890
    Soluble Therapeutics Closes on Second Investment Round

    Soluble Therapeutics Closes on Second Investment Round

    by John McCarter, MS

    Birmingham, AL- December 2013

    – Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO and product development company specializing in formulation optimization for protein-based Bioscience, announces that it has secured a second round of investment to support the expansion of its formulation development business. This expansion is necessary to meet continued demand for the company’s large molecule formulation service, as well as to accommodate two new research collaborations, one with a global Pharmaceutical Contract Manufacturing Organization (CMO) and one with a large US based pharmaceutical company, that could lead to exclusive licensing deals for the HSCTM Technology.

    The investment comes from the Targeted Technology Fund II out of San Antonio, TX – a group that has participated in prior funding rounds for the company. Soluble Therapeutics’ CEO, Dr. Joseph Garner, states “This funding represents a vote of confidence in the work that Soluble Therapeutics is doing and will allow us to continue expanding upon our initial success. We are very excited about the research collaborations kicking off in 2014 and further demonstrating the value of the HSCTM Technology in the marketplace.”

    About Soluble Therapeutics, Inc.

    Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years of combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSCTM Technology. For additional information visit

    About the HSCTM Technology

    The HSCTM Technology is a combination of high-throughput protein screening instrumentation and an artificial neural network. The instrumentation performs Self-Interaction Chromatography (SIC) to measure the effects of additives and excipients on the B22 value of proteins in solution. Positive B22 values are correlated with increased solubility and stability for the protein under study. By performing high-throughput SIC, the HSCTM Technology can do the work of 4,000 formulation assays in approximately one month. The HSCTM Technology is available on a contract research basis, or the HSCTM System can be purchased for use in laboratories across the world.

    John McCarter, MS
    Director – Business Development
    Soluble Therapeutics, Inc.
    Tel: (205) 451-9964